tbuckley/cabot-search huggingface dataset:
IDIOPATHIC RECURRING THROMBOPHLEBITIS
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE WEATHER
Authors: J. A. Hingeston
Journal: BMJ (1855)

JOUNAJ[Now.It, aln. a Ax action was not stong eough to brig up the contents 'hbi stomach.He went to bd, and rlept most of the da: in fact, he had no subsequent trouble, except a little gk1Ing from ndems of the uvula.I took out the stitches on the 28th, and found that the wouand had entirely healed; and so it remained.Of course the bony aperture still remains to be relieved by artificial MOM.
Letter: A rational approach to parenteral nutrition.
Journal: BMJ (1976)

dissented from the view that the possibility" of a direct relationship between multiple exposure to halothane and postoperative liver damage existed.They asked why the committee had not sought "expert opinion," presumably from anaesthetists, before publishing their circular letter.It is apparent that the two groups who were working contemporaneously have now come to the same conclusion.As a general practitioner who is also a very part-time worker for the CSM I hope I am not out of order in expressing the view that it is a pity that some degree of effective communication, co-operation, and co-ordination between the two groups was not effected at an early stage and the hope that a lesson has been learnt for the future.
Correction
Journal: Circulation (2005)

Table 3 (p 619): In the footnote entry "How to Use the Table," the example text states that Temporary transvenous pacing (TV) is Class IIb, whereas the table shows TV to be Class IIa.This should be Class IIa in both instances.• Table 4 (p 626): The footnote entry listing the source of the data is incorrect.The correct
JournalScan
Authors: G Aithal
Journal: Gut (2003)

▴ Spiegel BMR , Targownik L, Dulai GS, et al . The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med2003;138:795–806. [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Cyclooxygenase-2 (COX-2) inhibitors have a lower risk of GI bleeding with a similar analgesia efficacy but are more expensive than NSAIDs. Spiegel et al report a systematic review on the adverse events of COX-2 compared with NSAIDs and constructed a Markov model comparing the cost-effectiveness of these two alternatives. Their meta-analysis suggested that COX-2 inhibitors had a lower risk of dyspeptic symptoms (relative risk (RR) 0.77; 95% confidence intervals (CI) 0.74 to 0.81) and clinically significant ulcer complications (RR=0.50; 95% CI 0.40 to 0.63) compared to NSAIDs. The authors assumed that all NSAID patients with dyspepsia would be investigated with endoscopy, be prescribed long term proton pump inhibitor therapy and switch to a COX-2 inhibitor. They also assumed that there would be no difference in cardiovascular events between the two options. Despite these assumptions in favour of COX-2 inhibitors the model suggested this strategy would cost $275 809/QALY gain compared with prescribing Naproxen in 60 year old patients. If patients had a previous bleeding ulcer the cost would reduce to $55 803/QALY gained. This was cost effective for US budgets but would be too expensive for the UK and many European health care systems. COX-2 inhibitors are currently too expensive to recommend as alternatives to NSAIDs for average … [1]: {openurl}?query=rft.jtitle%253DAnnals%2Bof%2BInternal%2BMedicine%26rft.stitle%253DANN%2BINTERN%2BMED%26rft.issn%253D0003-4819%26rft.aulast%253DSpiegel%26rft.auinit1%253DB.%2BM.R.%26rft.volume%253D138%26rft.issue%253D10%26rft.spage%253D795%26rft.epage%253D806%26rft.atitle%253DThe%2BCost-Effectiveness%2Bof%2BCyclooxygenase-2%2BSelective%2BInhibitors%2Bin%2Bthe%2BManagement%2Bof%2BChronic%2BArthritis%26rft_id%253Dinfo%253Adoi%252F10.7326%252F0003-4819-138-10-200305200-00007%26rft_id%253Dinfo%253Apmid%252F12755551%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.7326/0003-4819-138-10-200305200-00007&link_type=DOI [3]: /lookup/external-ref?access_num=12755551&link_type=MED&atom=%2Fgutjnl%2F52%2F9%2F1382.atom [4]: /lookup/external-ref?access_num=000182920700003&link_type=ISI
Society Proceedings
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDICAL NEWS
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chemical characterization and bioactivity of polycyclic aromatic hydrocarbons from non-oxidative thermal treatment of pyrene-contaminated soil at 250-1,000 degrees C.
Authors: H Richter, V Risoul, A L Lafleur, E F Plummer, J B Howard, W A Peters
Journal: Environmental Health Perspectives (2000)

In this paper we report yields, identities, and mutagenicities of products from heating a polycyclic aromatic hydrocarbon (PAH)-contaminated, Superfund-related synthetic soil matrix without exogenous oxygen. We heated batch samples of soil pretreated with 5.08 wt% (by weight) pyrene in a tubular furnace under a constant flow of helium gas at 250, 500, 750, and 1,000 +/- 20 degrees C. Dichloromethane (DCM) extracts of cooled residues of heated soil and of volatiles condensed on a cold finger after 1 sec residence time at furnace temperature were assayed gravimetrically and analyzed for PAH by HPLC, HPLC coupled to mass spectrometry, and gas chromatography coupled to mass spectrometry. All four temperatures volatilized pyrene and generated other PAHs, including alkylated pyrenes. We detected bioactive PAHs in the product volatiles: cyclopenta[cd]pyrene (CPP) at 750 and 1,000 degrees C and benzo[a]pyrene (BaP) at 1,000 degrees C. We found a clean soil residue, i.e., no pyrene or other DCM extracts, only at 750 degrees C. Control experiments with uncontaminated soil, pyrene, and Ottawa sand plus 4.89 wt% pyrene revealed no CPP or BaP production from soil itself, but these experiments imply that pyrene interactions with soil, e.g., soil-bound silica, stimulate CPP and BaP production. We detected mutagenicity to human diploid lymphoblasts (in vitro) in volatiles from 1,000 degrees C heating of soil plus pyrene and sand plus pyrene, and in the residue from 500 degrees C heating of soil plus pyrene. Three plausible pathways for pyrene conversion to other PAHs are a) a reaction with light gas species, e.g., soil- or pyrene-derived acetylene; b) loss of C(2)-units followed by reaction with a PAH; and c) dimerization with further molecular weight growth via cyclodehydrogenation. This study shows that thermal treatment of PAH-polluted soil may generate toxic by-products that require further cleanup by oxidation or other measures.
HUMAN HAPPINESS A BUSINESS ASSET
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Peritoneal Ultrafiltration Dialysis [J Clin Invest 45:950 (June) 1966]
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PLACE OF THE PHYSICIAN IN THE SOCIAL SCHEME
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lipid and Lipoprotein Levels in Patients With IDDM: Diabetes Control and Complication Trial Experience
Journal: Diabetes Care (1992)

To compare lipid and lipoprotein levels in patients with insulin-dependent diabetes mellitus (IDDM) with values in similarly aged nondiabetic subjects and analyze the effects of demographic variables, metabolic control, and other factors on the lipid and lipoprotein levels in the diabetic population.Fasting total cholesterol, triglyceride, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol levels measured during screening for the Diabetes Control and Complications Trial (DCCT) in 1569 generally healthy IDDM patients, between the ages of 13 and 40 yr and with 1-15 yr diabetes duration, were compared with values obtained with similar methods in the Lipid Research Clinics (LRC) prevalence study of nondiabetic individuals.When similarly aged groups of IDDM and nondiabetic subjects were compared, higher total and LDL cholesterol and lower HDL cholesterol lipid profiles were restricted to younger (13-24 yr) female diabetic subjects. In general, IDDM males and older IDDM females had similar or slightly less atherogenic profiles than similarly aged nondiabetic subjects. Metabolic control, measured by HbA1c, and body weight (% of ideal body wt) correlated positively with total cholesterol, LDL cholesterol, and triglyceride levels.Lipid and lipoprotein levels in the generally healthy IDDM volunteers for the DCCT are similar to those in the nondiabetic population. More atherogenic profiles were present only in younger IDDM women compared with nondiabetic women. The differences between the DCCT data and older studies that demonstrated more profound abnormalities in lipid levels in IDDM populations may reflect patient selection and/or changes in dietary patterns (higher-carbohydrate and lower-fat content) and in glucose control that has occurred in recent years.
Sudek's atrophy v disuse osteoporosis
Authors: R. Kilcoyne
Journal: JAMA (1983)

<h3>To the Editor.—</h3> The Jan 7 TOPICS IN RADIOLOGY (1983;249:77) discussed causes for the "bone within a bone" appearance. I disagree with Frager and Subbarao's description of subcortical osteoporosis in the round bones of the carpus and tarsus as being indicative of acute reflex dystrophy syndrome (Sudeck's atrophy). This type of resorption of bone is commonly seen after immobilization, usually for treatment of fracture in the affected limb. The development of a zone of translucency beneath the subchondral plate of the talus in cases of talar fracture is considered a good prognostic sign and not a sign of reflex dystrophy. The term<i>Hawkins' sign</i>has been applied to this talar finding to indicate that avascular necrosis will not develop in the proximal fracture fragment.<sup>1</sup> Reflex sympathetic dystrophy is a clinical diagnosis based on the presence of burning pain, trophic changes with swollen, pale, stiff digits, and the roentgenographic sign
THE PATHOLOGY OF FIBRINOUS BRONCHITIS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase 3 open-label, randomized, multicenter study of imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer.
Authors: Richard Dale Huhn, Jamie Lowe, Michele M Grady, Corina Candiani Taitt, Ada H. Braun
Journal: Journal of Clinical Oncology (2015)

TPS3635 Background: Imprime PGG (Imprime) is a beta-1,3/1,6 glucan complex carbohydrate biologic, which harnesses innate immune effector cells to enhance killing of antibody-targeted, complement-opsonized tumor cells. In a phase 2 single-arm clinical trial in metastatic colorectal cancer (mCRC), the combination of Imprime with cetuximab resulted in 24% objective response rate (ORR), 62% disease control rate (DCR), and median time to progression (TTP) of 12 wks (Tamayo ME, Ann Onc 2010), representing approximate 100% increases vs historical control (Cunningham, NEJM 2004). ORR was 45%, DCR, 82% and TTP of 24 wks in patients (pts) with KRAS wild-type (WT) tumors (post hoc analysis). Single-agent cetuximab has been shown to improve ORR, progression-free survival (PFS) and overall survival (OS) in pts with epidermal growth factor receptor (EGFR) expressing, KRAS WT mCRC who failed oxaliplatin- and irinotecan-based therapy or are intolerant to irinotecan. The mechanism of action of cetuximab is thought to rely on competitive blockade of endogenous ligand binding and downstream signaling, internalization and down regulation of EGFR, as well as antibody-dependent cellular cytotoxicity (ADCC) (Erbitux USPI). The current trial, sponsored by Biothera and registered with ClinicalTrials.gov (NCT01309126) is to confirm these findings in phase 3. Methods: Eligible pts have received prior oxaliplatin- and irinotecan-based therapy or are intolerant to irinotecan, have measurable disease and ECOG performance status of 0 or 1. Approximately 795 pts will be randomized 2:1, stratified by geographic region, prior chemotherapy and site, to receive weekly open-label Imprime plus cetuximab or cetuximab alone. The primary endpoint of the study is OS and the primary analysis will occur when ~709 deaths have occurred. Secondary endpoints include PFS, ORR (based on RECIST 1.1), quality of life, safety and pharmacokinetics. Exploratory endpoints include biomarker analyses. Pt screening and enrollment is underway in the United States and Europe. Clinical trial information: NCT01309126.
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.
Authors: Shannon Puhalla, Sharon Wilks, Adam Brufsky, Joyce O'Shaughnessy, Lee Steven Schwartzberg, Erhan Berrak, James Song, David Cox, Linda T. Vahdat
Journal: Journal of Clinical Oncology (2014)

635^ Background: Eribulin mesylate, a novel nontaxane microtubule dynamics inhibitor in the halichondrin class of antineoplastic drugs, is indicated for women with MBC who previously received ≥2 chemotherapy regimens in the metastatic setting. Primary data from a phase 2 trial on first-line combination eribulin + trastuzumab (TRAS) in HER2+ patients (pts) showed a 71% objective response rate (ORR) and tolerability consistent with the known profile of these agents. Here we present prespecified endpoint data for this study by prior TRAS use. Methods: Pts with HER2+ MBC who had not received prior chemotherapy for MBC received eribulin mesylate 1.4 mg/m2IV on days 1 and 8 of each 21-day cycle and initial TRAS (8 mg/kg IV/day 1), followed by 6 mg/kg/day 1 of each subsequent cycle. Response, progression-free survival (PFS), and tolerability were assessed in patients who had and had not received prior TRAS treatment. Results: The 52 pts (median age, 59.5 years) received combination eribulin + TRAS, for a median treatment duration of ~30 weeks; 40% (n=21) were previously treated with TRAS in the neo-adjuvant / adjuvant setting. There was median of 23 months since completion of adjuvant treatment prior to retreatment with eribulin + TRAS for first-line MBC.Efficacy, assessed by ORR, clinical benefit rate (CBR), PFS, and duration of response (DOR), was largely consistent in pts who received prior TRAS relative to pts who had not received prior TRAS (see table). Overall, Grade (G) 3-5 adverse events (AEs), treatment-related AEs (TRAEs), and discontinuations (d/c) were similar between groups (Table). Conclusions: In this phase 2 single-arm trial in pts with HER2+ MBC, eribulin + TRAS demonstrated activity and was well tolerated as first-line treatment, irrespective of prior (neo) adjuvant TRAS treatment. Clinical trial information: NCT01269346. HER2+ pts (N=52) w/ prior TRAS w/o prior TRAS n (%) 21 (40) 31 (60) ORR, n (%) 13 (62) 24 (77) CBR, n (%) 17 (81) 27 (87) PFS, m (median) 11.5 12.2 DOR, m (median) 9.5 11.8 AEs, G3-4, n (%) 16 (76) 21 (68) AEs, G5, n (%) 0 (0) 1 (2) TRAE, n (%) 21 (100) 31 (100) AEs leading to d/c, n (%) 5 (24) 6 (19)